FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912906273> ?p ?o ?g. }

• W2912906273 endingPage "1367" @default.
• W2912906273 startingPage "1363" @default.
• W2912906273 abstract "To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive individuals. The study design was observational. Patients were HIV-positive, ART-naive subjects starting raltegravir, elvitegravir/cobicistat or dolutegravir with two NRTIs. The primary endpoint was time to treatment failure, i.e. occurrence of virological failure (first of two consecutive plasma HIV RNAs ≥200 copies/mL after 24 weeks) or INSTI discontinuation for any reason apart from simplification. Secondary endpoints were INSTI discontinuation due to toxicity/intolerance and CD4 count response. Survival analysis was done using Kaplan–Meier and Cox regression. Two thousand and sixteen patients were included: 310 (15.4%) started raltegravir-based regimens, 994 (49.3%) started dolutegravir-based regimens and 712 (35.3%) started elvitegravir/cobicistat-based regimens. Over a median of 11 months, 167 patients experienced treatment failure; the 1 year probability of treatment failure was 6.5% for raltegravir, 5.4% for dolutegravir and 6.7% for elvitegravir/cobicistat (P = 0.001). Sixty-eight patients (3.4%) discontinued INSTIs owing to toxicity/intolerance. By multivariable analysis, patients starting raltegravir had a 2.03-fold (95% CI = 1.2–3.2) higher risk and patients on elvitegravir/cobicistat a 1.88-fold (95% CI = 1.2–2.9) higher risk of treatment failure versus dolutegravir; there was no difference in risk of discontinuation due to toxicity/intolerance when comparing dolutegravir and raltegravir and marginal evidence for a difference when comparing elvitegravir/cobicistat and dolutegravir (adjusted relative hazard = 1.94 for elvitegravir/cobicistat versus dolutegravir, 95% CI = 1.00–3.76, P = 0.05). In our real-life setting, INSTI-based regimens showed high potency and durability. Among regimens currently recommended in Europe, those including dolutegravir are associated with a lower risk of treatment failure." @default.
• W2912906273 created "2019-02-21" @default.
• W2912906273 creator A5002495981 @default.
• W2912906273 creator A5032359240 @default.
• W2912906273 creator A5034279162 @default.
• W2912906273 creator A5047438814 @default.
• W2912906273 creator A5047814523 @default.
• W2912906273 creator A5049035721 @default.
• W2912906273 creator A5064636041 @default.
• W2912906273 creator A5068011395 @default.
• W2912906273 creator A5076739061 @default.
• W2912906273 creator A5078701955 @default.
• W2912906273 creator A5085354537 @default.
• W2912906273 creator A5089618460 @default.
• W2912906273 date "2019-01-29" @default.
• W2912906273 modified "2023-10-06" @default.
• W2912906273 title "Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting" @default.
• W2912906273 cites W1985646480 @default.
• W2912906273 cites W2045330844 @default.
• W2912906273 cites W2068866500 @default.
• W2912906273 cites W2094241860 @default.
• W2912906273 cites W2139430929 @default.
• W2912906273 cites W2145467751 @default.
• W2912906273 cites W2161993838 @default.
• W2912906273 cites W2554692247 @default.
• W2912906273 cites W2556153964 @default.
• W2912906273 cites W2608989554 @default.
• W2912906273 cites W2728117782 @default.
• W2912906273 cites W2804884576 @default.
• W2912906273 doi "https://doi.org/10.1093/jac/dky566" @default.
• W2912906273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30698801" @default.
• W2912906273 hasPublicationYear "2019" @default.
• W2912906273 type Work @default.
• W2912906273 sameAs 2912906273 @default.
• W2912906273 citedByCount "19" @default.
• W2912906273 countsByYear W29129062732019 @default.
• W2912906273 countsByYear W29129062732020 @default.
• W2912906273 countsByYear W29129062732021 @default.
• W2912906273 countsByYear W29129062732022 @default.
• W2912906273 countsByYear W29129062732023 @default.
• W2912906273 crossrefType "journal-article" @default.
• W2912906273 hasAuthorship W2912906273A5002495981 @default.
• W2912906273 hasAuthorship W2912906273A5032359240 @default.
• W2912906273 hasAuthorship W2912906273A5034279162 @default.
• W2912906273 hasAuthorship W2912906273A5047438814 @default.
• W2912906273 hasAuthorship W2912906273A5047814523 @default.
• W2912906273 hasAuthorship W2912906273A5049035721 @default.
• W2912906273 hasAuthorship W2912906273A5064636041 @default.
• W2912906273 hasAuthorship W2912906273A5068011395 @default.
• W2912906273 hasAuthorship W2912906273A5076739061 @default.
• W2912906273 hasAuthorship W2912906273A5078701955 @default.
• W2912906273 hasAuthorship W2912906273A5085354537 @default.
• W2912906273 hasAuthorship W2912906273A5089618460 @default.
• W2912906273 hasBestOaLocation W29129062732 @default.
• W2912906273 hasConcept C126322002 @default.
• W2912906273 hasConcept C142462285 @default.
• W2912906273 hasConcept C159047783 @default.
• W2912906273 hasConcept C2777068322 @default.
• W2912906273 hasConcept C2777302000 @default.
• W2912906273 hasConcept C2778715236 @default.
• W2912906273 hasConcept C2779502633 @default.
• W2912906273 hasConcept C2780404665 @default.
• W2912906273 hasConcept C2780524789 @default.
• W2912906273 hasConcept C2993143319 @default.
• W2912906273 hasConcept C3013748606 @default.
• W2912906273 hasConcept C71924100 @default.
• W2912906273 hasConcept C98274493 @default.
• W2912906273 hasConceptScore W2912906273C126322002 @default.
• W2912906273 hasConceptScore W2912906273C142462285 @default.
• W2912906273 hasConceptScore W2912906273C159047783 @default.
• W2912906273 hasConceptScore W2912906273C2777068322 @default.
• W2912906273 hasConceptScore W2912906273C2777302000 @default.
• W2912906273 hasConceptScore W2912906273C2778715236 @default.
• W2912906273 hasConceptScore W2912906273C2779502633 @default.
• W2912906273 hasConceptScore W2912906273C2780404665 @default.
• W2912906273 hasConceptScore W2912906273C2780524789 @default.
• W2912906273 hasConceptScore W2912906273C2993143319 @default.
• W2912906273 hasConceptScore W2912906273C3013748606 @default.
• W2912906273 hasConceptScore W2912906273C71924100 @default.
• W2912906273 hasConceptScore W2912906273C98274493 @default.
• W2912906273 hasFunder F4320312382 @default.
• W2912906273 hasIssue "5" @default.
• W2912906273 hasLocation W29129062731 @default.
• W2912906273 hasLocation W29129062732 @default.
• W2912906273 hasLocation W29129062733 @default.
• W2912906273 hasOpenAccess W2912906273 @default.
• W2912906273 hasPrimaryLocation W29129062731 @default.
• W2912906273 hasRelatedWork W1557841390 @default.
• W2912906273 hasRelatedWork W1790877993 @default.
• W2912906273 hasRelatedWork W1973819232 @default.
• W2912906273 hasRelatedWork W2020610488 @default.
• W2912906273 hasRelatedWork W2021395278 @default.
• W2912906273 hasRelatedWork W2323575706 @default.
• W2912906273 hasRelatedWork W2325222779 @default.
• W2912906273 hasRelatedWork W2912906273 @default.
• W2912906273 hasRelatedWork W2913317838 @default.
• W2912906273 hasRelatedWork W4252563160 @default.
• W2912906273 hasVolume "74" @default.

• next